Alzheimer's disease cerebrospinal fluid biomarkers predict cognitive decline in lewy body dementia.
Alzheimer's disease pathologies are common in dementia with Lewy bodies, but their clinical relevance is not clear. CSF biomarkers amyloid beta 1-42, total tau, and tau phosphorylated at threonine 181 reflect Alzheimer's disease neuropathology antemortem. In PD, low CSF amyloid beta 1-42 predict long-term cognitive decline, but little is known about these biomarkers as predictors for cognitive decline in Lewy body dementia. The aim of this study was to assess whether Alzheimer's disease CSF biomarkers predict cognitive decline in Lewy body dementia.



From a large European dementia with Lewy bodies multicenter study, we analyzed baseline Alzheimer's disease CSF biomarkers and serial MMSE (baseline and 1- and 2-year follow-up) in 100 patients with Lewy body dementia. Linear mixed-effects analyses, adjusted for sex, age, baseline MMSE, and education, were performed to model the association between CSF biomarkers and rate of cognitive decline measured with MMSE. An Alzheimer's disease CSF profile was defined as pathological amyloid beta 1-42 plus pathological total tau or phosphorylated tau.



The Alzheimer's disease CSF profile, and pathological levels of amyloid beta 1-42, were associated with a more rapid decline in MMSE (2.2 [P < 0.05] and 2.9 points difference [P < 0.01], respectively). Higher total tau values showed a trend toward association without statistical significance (2.0 points difference; P = 0.064), whereas phosphorylated tau was not associated with decline.



Reduced levels of CSF amyloid beta 1-42 were associated with more rapid cognitive decline in Lewy body dementia patients. Future prospective studies should include larger samples, centralized CSF analyses, longer follow-up, and biomarker-pathology correlation. © 2016 International Parkinson and Movement Disorder Society.
Fundació ACE, Alzheimer Research Center and Memory Clinic, Institut Català de Neurociències Aplicades, Barcelona, Spain.
Carla
C
Abdelnour
Alzheimer Center, Department of Neurology, VU Medical Center, Amsterdam, The Netherlands.
Inger
I
van Steenoven
Clinical Memory Research Unit, Department of Clinical Sciences, Lund University, Malmö, Sweden.
Elisabet
E
Londos
Neuropsychology Unit and Geriatric Day Hospital (Strasbourg Resource and Research Memory Center, CMRR), University Hospital of Strasbourg and ICube laboratory, FMTS, University of Strasbourg and CNRS, Strasbourg, France.
Frédéric
F
Blanc
Research Department, Stavanger University Hospital, Stavanger, Norway.|Department of Mathematics and Natural Sciences, University of Stavanger, Stavanger, Norway.
Bjørn
B
Auestad
Department of Neurology, University Medical Center, Ljubljana, Slovenia.
Milica G
MG
Kramberger
Institute of Neuroscience and Physiology, Department of Psychiatry and Neurochemistry, the Sahlgrenska Academy at the University of Gothenburg, Mölndal, Sweden.|Department of Molecular Neuroscience, UCL Institute of Neurology, London, United Kingdom.
Henrik
H
Zetterberg
Paracelsus-Elena-Klinik, Kassel and University Medical Center, Department of Neurosurgery and Institute of Neuropathology, Göttingen, Germany.
Brit
B
Mollenhauer
Fundació ACE, Alzheimer Research Center and Memory Clinic, Institut Català de Neurociències Aplicades, Barcelona, Spain.
Mercè
M
Boada
Research Department, Stavanger University Hospital, Stavanger, Norway.|Karolinska Institutet, Department of Neurobiology, Care sciences and Society (NVS), Center for Alzheimer Research Division for Neurogeriatrics, Stockholm, Sweden.
Dag
D
Aarsland
D000368:Aged; D000369:Aged, 80 and over; D000544:Alzheimer Disease / Q000134:cerebrospinal fluid* / Q000503:physiopathology; D016229:Amyloid beta-Peptides / Q000134:cerebrospinal fluid; D015415:Biomarkers; D018450:Disease Progression; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D020961:Lewy Body Disease / Q000134:cerebrospinal fluid* / Q000503:physiopathology; D008297:Male; D000073216:Mental Status and Dementia Tests; D010446:Peptide Fragments / Q000134:cerebrospinal fluid; D011379:Prognosis; D016875:tau Proteins / Q000134:cerebrospinal fluid
D016229:Amyloid beta-Peptides; D015415:Biomarkers; D010446:Peptide Fragments; C075222:amyloid beta-protein (1-42); D016875:tau Proteins
CSF biomarkers; Lewy body dementia; cognitive decline